Home

Do you know the targets of your ligand?

Pretest

Flow TriCEPS / TAMRA-TriCEPS / Services/Kit

Cell selection and optimization of binding conditions for target identification

More about

Target identification

LRC-TriCEPS / LRC-HATRIC Services

Identification of targets and off targets on the cell surface of living cells

More about

Confirmation

Flow TriCEPS combined with siRNA knock down

Knock down the identified targets and test if ligand binding is reduced

More about

How we support you

Dualsystems Biotech is a service provider for custom proteomics for industry and academia. We are a biotech company specialized in elucidating protein-protein interaction in living cells focusing at the cell membrane. We identify the targets of your extracellular ligands (small molecules, peptides, proteins, antibodies, ADC’s, Fc-fusion proteins, and viruses) using the ligand-receptor capture LRC-TriCEPS and the HATRIC-LRC platforms. During the interaction of your ligand of interest and its unknown targets and off-targets the cells are still alive and the unknown targets are in their natural microenvironment. There is no need to genetically modify the cells and any cell type (cell lines or primary cells) can be used.

We elucidate in a 3-step approach the mode of action of your ligand of interest.

With Flow-TriCEPS (Pretest) we developed a tool to visualize the binding of your ligand on cells using flow cytometry. Alternatively, with TAMRA-TriCEPS we can visualize the binding of TriCEPS coupled ligand to the cells also by confocal microscopy. During those pretests, we identify the best binding conditions (time, temperature, pH, co-factors, and cell activation) for your ligand of interest without the need of a detection antibody. Further, we provided Flow-TriCEPS as a kit so that you can test in your functional assays if your TriCEPS coupled ligand is still active. Flow-TriCEPS and TAMRA-TriCEPS couple the ligand by using primary amines (N-Term and Lysines) and since it contains a visualization function, binding can be detected by flow cytometry or confocal microscopy.

Once the optimal binding conditions are identified the next step can be initiated. In the identification studies, we use TriCEPS or HATRIC coupled ligand to treat the cells. The cells are mildly oxidized so that the second arm of TriCEPS / HATRIC binds with a covalent bond to the glycans of the targets/off-targets. The third arm of TriCEPS is used to enrich the surface proteins. Proteins are identified through bottom-up proteomics, relatively quantified and compared to one or several controls (we advise to use two controls). The most enriched proteins are the target candidates for the respective ligand. In general, we expect a low number of target candidates (less than 5).

In the third step, the identified target candidates can be downregulated using siRNA and if a reduced binding of the ligand of interest is observed with Flow-TriCEPS or TAMRA-TriCEPS compared to the wild type cells the identified candidates are confirmed.

News Dualsystems

Licensing Agreement with ETH Zurich on LRC technoloy

June 24, 2013

Dualsystems Biotech closes Licensing Agreement with ETH Zurich on Ligand Receptor Capture (LRC) technology Dualsystems Biotech has licensed an innovative technology to discover cell-surface receptors for a vast range of ligands of interest. LRC is centered around an innovative trifunctional chemoproteomic reagent named TriCEPS, which enables the unbiased identification of cell surface receptors for many…

Pretest

Flow TriCEPS / TAMRA-TriCEPS

Test the optimal binding conditions of your ligand to the unknown targets (time, temperature, pH) using flow cytometry or confocal microscopy
Find the best cell type for your identification experiment
Assess if co-factors are needed for your ligand to bind its targets
Use TriCEPS coupled ligand in your functional assay prior to the identification experiment

Target identification

LRC-TriCEPS / LRC-HATRIC

Identification of the targets and off-targets of your ligand of interest on living cells using the LC-MS/MS based LRC-TriCEPS and LRC-HATRIC technology platforms
No genetic manipulation needed
Target proteins are in their natural microenvironment, the cell-membrane of living cells and therefore correctly modified and in the correct tertiary structure surrounded by their naturally occurring neighbouring proteins

Confirmation

Flow TriCEPS combined with siRNA knock down

Confirm the identified targets of your ligand by siRNA knock-down. Test by flow cytometry if the binding of your ligand is reduced when the identified target is knocked down
Can be performed for most targets unless they are relevant for cell survival
No antibodies against the targets needed

Elucidate the mode of action using the LRC-TriCEPS platforms

Download flyer

We identify targets / off-targets of your ligand

Interested?

Get in touch

Customers Testimonials – LRC-TriCEPS Service

Testimonials from our customers who have used the LRC-TriCEPS technology – in collaboration with Dualsystems Biotech AG.

Helmholtz Munich

We used the LRC-TriCEPS technology from Dualsystems to identify interacting proteins for a tumor-secreted factor on the surface of differentiated myotubes. The main interaction partner identified through the LRC-TriCEPS workflow could be confirmed using independent experimental methods. This discovery proved pivotal for elucidating the underlying mechanism of action responsible for the phenotypic effects we had observed and facilitated further development toward specific therapeutic targeting.

We highly appreciated the professional and dedicated support provided by the Dualsystems team throughout the project, which contributed to the smooth and successful execution of the study.

Dr. Mauricio Berriel Diaz
Deputy Director &
Head of Division Metabolism and Cancer
Institute for Diabetes and Cancer (IDC)

www.helmholtz-munich.de

2026-03-10T15:59:33+00:00

We used the LRC-TriCEPS technology from Dualsystems to identify interacting proteins for a tumor-secreted factor on the surface of differentiated myotubes. The main interaction partner identified through the LRC-TriCEPS workflow could be confirmed using independent experimental methods. This discovery proved pivotal for elucidating the underlying mechanism of action responsible for the phenotypic effects we had observed and facilitated further development toward specific therapeutic targeting. We highly appreciated the professional and dedicated support provided by the Dualsystems team throughout the project, which contributed to the smooth and successful execution of the study. Dr. Mauricio Berriel Diaz Deputy Director & Head of Division Metabolism and Cancer Institute for Diabetes and Cancer (IDC) www.helmholtz-munich.de

https://www.dualsystems.com/testimonials/helmholtz-munich/

University Hospital of Lausanne (CHUV)

We collaborated with DualSystems Biotech AG to perform LRC-TriCEPS experiments aimed at identifying cellular factors involved in Zika virus infection. The entire process—from initial discussions through to data delivery—was carried out with exceptional professionalism and scientific rigor.

Thanks to their LRC-TriCEPS platform, we were able to identify a cellular factor playing a major role in Zika virus entry. This unique method was applied to living cells without the need for genetic modification. In our case, the method worked robustly across three different cell types. Notably, it enabled the identification of an unexpected target at the cell surface that would likely have been missed by standard screening approaches, as the protein lacks a classical membrane anchor. What impressed us most was that the implication of this target, discovered via their screening, was subsequently confirmed in our in vitro studies using different cellular models.

We greatly appreciated the collaboration with the DualSystems Biotech AG team. Their expertise, responsiveness, and willingness to support our project at every stage were key to its success. The data provided were of high quality and well presented, facilitating downstream interpretation and validation.

Milos Stojanov, PhD - Head of the Materno-fetal and Obstetrics Research Unit - University Hospital of Lausanne (CH)

Miloš Stojanov, PhD | Senior Lecturer (MER1)
Head of the Materno-fetal and Obstetrics Research Unit
Department Woman-mother-child (DFME)
1011 Lausanne
Tél: +41 21 314 05 17

2025-04-04T12:42:13+00:00

We collaborated with DualSystems Biotech AG to perform LRC-TriCEPS experiments aimed at identifying cellular factors involved in Zika virus infection. The entire process—from initial discussions through to data delivery—was carried out with exceptional professionalism and scientific rigor. Thanks to their LRC-TriCEPS platform, we were able to identify a cellular factor playing a major role in Zika virus entry. This unique method was applied to living cells without the need for genetic modification. In our case, the method worked robustly across three different cell types. Notably, it enabled the identification of an unexpected target at the cell surface that would likely have been missed by standard screening approaches, as the protein lacks a classical membrane anchor. What impressed us most was that the implication of this target, discovered via their screening, was subsequently confirmed in our in vitro studies using different cellular models. We greatly appreciated the collaboration with the DualSystems Biotech AG team. Their expertise, responsiveness, and willingness to support our project at every stage were key to its success. The data provided were of high quality and well presented, facilitating downstream interpretation and validation. Milos Stojanov, PhD - Head of the Materno-fetal and Obstetrics Research Unit - University Hospital of Lausanne (CH) Miloš Stojanov, PhD | Senior Lecturer (MER1) Head of the Materno-fetal and Obstetrics Research Unit Department Woman-mother-child (DFME) 1011 Lausanne Tél: +41 21 314 05 17

https://www.dualsystems.com/testimonials/university-hospital-of-lausanne-chuv/

OncoLille Cancer Institute

We aim to identify the ligand of a receptor, but due to the low affinity of the interaction other approaches that have been tried failed. Paul Helbling and the DualSystem team provided a great support and critical insights for performing the ligand identification using the LCR-TriCEPS technology. We found now a candidate ligand that we are currently validating with promising results. DualSystem team has been really professional and of great support in this process and we plan to work again with them in the future.

Best,

Silvia Gaggero, PhD
Mitra Lab, Inserm
OncoLille Cancer Institute
Lille, France

2024-06-06T12:25:14+00:00

https://www.dualsystems.com/testimonials/oncolille-cancer-institute/

AstraZeneca

We needed to identify the target of an antibody from a phenotypic screening approach using a difficult iPSC-derived cell line and reached-out to DualSystems and their LRC-TriCEPS technology after an earlier attempt at target deconvolution using an array of membrane targets had failed. The support I got from Paul Helbling and his team was great and as someone who was unfamiliar with the approach, I really appreciated the advice and guidance that I got. At the end of the process the top candidate from the analysis was confirmed as the target of the antibody – a brilliant result! Overall, a really positive experience and I would definitely recommend DualSystems.

James Dodgson
AstraZeneca
Cambridge, UK.

2023-05-24T20:08:08+00:00

https://www.dualsystems.com/testimonials/astrazeneca/

UCF College of Medicine

“DualSystems LRC-TriCEPS platform helped us in the identification of a novel allergen receptor. This finding was central to our recently published work and funded grant! DualSystems was very helpful during the entire process, if you are considering using this platform, do not hesitate. The process is straightforward and the support is excellent!”

Justine Tigno-Aranjuez, Ph.D.
Assistant Professor of Medicine
UCF College of Medicine

2023-03-16T06:40:12+00:00

https://www.dualsystems.com/testimonials/ucf-college-of-medicine/

Cohbar

DualSystems' LRC-TriCEPS platform was exactly what we needed to identify potential targets and guide us in mechanism of action studies for our peptide program. They helped us every step of the way -- from understanding their capabilities, to guiding study design, and supporting sample preparation. The report they delivered exceeded our expectations and truly stands out from data reports we've received from other companies. They were readily available to answer questions and discuss concerns or outcomes. We are very encouraged by the results and are currently following up on the targets identified. We highly recommend working with DualSystems and incorporating the LRC-TriCEPS platform into your program. We look forward to working with the DualSystems team again in the future.

Dr. Lindsay Stark
Drug Discovery Scientist at CohBar

2023-01-18T08:14:48+00:00

https://www.dualsystems.com/testimonials/cohbar/

Technical University of Munich

Technical University of Munich – Institute of Experimental Oncology and Therapy Research

Using LRC-TriCEPS, we aimed to identify novel direct cell surface receptors of our ligand of interest.
At any time, we experienced great support of Dualsystems Biotech. They kindly helped to find optimal conditions for our purposes and provided help with any kind of question before, during and after the experiment. LRC-TriCEPS allowed us to identify novel cell surface receptors of our ligand, which we could successfully validate in different cell types and with different biochemical assays. We can fully recommend Dualsystems Biotech and are looking forward to perform further analyses using LRC-TriCEPS.

Prof. Dr. rer. nat. Achim Krüger
Institute of Experimental Oncology and Therapy Research
Klinikum rechts der Isar, Technical University of Munich

2022-07-27T14:23:02+00:00

Technical University of Munich – Institute of Experimental Oncology and Therapy Research Using LRC-TriCEPS, we aimed to identify novel direct cell surface receptors of our ligand of interest. At any time, we experienced great support of Dualsystems Biotech. They kindly helped to find optimal conditions for our purposes and provided help with any kind of question before, during and after the experiment. LRC-TriCEPS allowed us to identify novel cell surface receptors of our ligand, which we could successfully validate in different cell types and with different biochemical assays. We can fully recommend Dualsystems Biotech and are looking forward to perform further analyses using LRC-TriCEPS. Prof. Dr. rer. nat. Achim Krüger Institute of Experimental Oncology and Therapy Research Klinikum rechts der Isar, Technical University of Munich

https://www.dualsystems.com/testimonials/technical-university-of-munich/

University of Miyazaki

We appreciate the support of Dualsystems Biotech and their LRC-TriCEPS technology we were able to identify a binding protein for our insulinotropic peptide

Hideyuki Sakoda, MD, PhD
Associate professor
Department of Biological Sciences, Faculty of Medicine, University of Miyazaki, Japan.

2022-04-19T11:45:22+00:00

We appreciate the support of Dualsystems Biotech and their LRC-TriCEPS technology we were able to identify a binding protein for our insulinotropic peptide Hideyuki Sakoda, MD, PhD Associate professor Department of Biological Sciences, Faculty of Medicine, University of Miyazaki, Japan.

https://www.dualsystems.com/testimonials/university-of-miyazaki/

Lund University Diabetes Centre

We wanted to use LRC-TriCEPS to characterise the mechanism of action of our ligand of interest. Not only were several candidate targets identified but we have successfully validated two of these receptors in insulin producing beta cells. DualSystems Biotech were very helpful and involved from study design, to experiments and reporting. Even after the initial report, DualSystems Biotech have answered follow up queries and provided assistance regarding publications. I highly recommend the LRC-TriCEPS technology and DualSystems Biotech and Paul Helbling and his team to work with.

Dualsystems-Testimonial-Lund-University

Dr. Claire L. Lyons,
Associate Researcher
Unit of Medical Protein Science
Lund University Diabetes Centre
Sweden

2021-10-25T05:58:59+00:00

https://www.dualsystems.com/testimonials/lund-university-diabetes-centre/

Australian National University

“We had a challenging project where we aimed to discover the receptor of our ligand of interest in primary human cells. Dualsystems Biotech took the challenge and provided outstanding support throughout the entire process, from the experimental design to data analysis. Using their LRC-TriCEPS technology, we could identify a candidate receptor and additional downstream interacting partners that we have now validated. We look forward to new collaborations and discoveries with Dr Paul Helbling and his team”. – Prof Carola Vinuesa, ANU

The Australian National University
Co-Director, Centre for Personalised Immunology, NHMRC Centre of Research Excellence
College of Health & Medicine
The Australian National University

2021-01-11T08:16:02+00:00

“We had a challenging project where we aimed to discover the receptor of our ligand of interest in primary human cells. Dualsystems Biotech took the challenge and provided outstanding support throughout the entire process, from the experimental design to data analysis. Using their LRC-TriCEPS technology, we could identify a candidate receptor and additional downstream interacting partners that we have now validated. We look forward to new collaborations and discoveries with Dr Paul Helbling and his team”. – Prof Carola Vinuesa, ANU The Australian National University Co-Director, Centre for Personalised Immunology, NHMRC Centre of Research Excellence College of Health & Medicine The Australian National University

https://www.dualsystems.com/testimonials/australian-national-university/

Harvard Medical School, Brigham and Women’s Hospital

We used DualSystems to help identify a potential novel receptor for a ligand that despite being studied for decades had unclear catabolism mechanisms involving its receptor mediated uptake. The DualSystems team will walk you through the process, including early validation of your ligand being used for this technology, data collection and analysis, and provide an easy to follow report on the findings. For anyone interested in receptor-ligand interactions, DualSystems and the TriCEPS approach is worth strongly considering involving in your research program, as it can quickly help identify receptors that would have been very difficult to do so without.

Maximillian Rogers, PhD
Research Scientist
Harvard Medical School, Brigham and Women's Hospital
Department of Medicine, Cardiovascular Division
Boston, MA

2020-11-09T13:27:52+00:00

https://www.dualsystems.com/testimonials/harvard-medical-school-brigham-and-womens-hospital/

Center for Biomolecular & Cellular Structure, Institute for Basic Science

“It was my great pleasure to collaborate with Dualsystems Biotech. We have been tested various proteomic analysis to identify the specific receptor for our secreted ligand. But, only LRC-TriCEPS experiment successfully gave us a right answer, because this receptor and ligand interactions were indeed relatively weaker than other general receptor and ligand interactions. The team very kindly consulted the whole experimental steps from the experimental design to the final data analysis. We are now going to use TriCEPS again for several other secreted ligands with a great hope for discovery of new receptors. Best Regards, Ho Min Kim”

Associate Professor
Graduate School of Medical Science and Engineering, KAIST
Chief Investigator
Center for Biomolecular & Cellular Structure, Institute for Basic Science (IBS)

2020-08-12T13:02:47+00:00

https://www.dualsystems.com/testimonials/center-for-biomolecular-cellular-structure-institute-for-basic-science/

Department of Internal Medicine Erasmus MC

We were fortunate to partner with Dualsystems Biotech AG to discover cell-surface targets for the short-peptide ligand we had been working on for several years. We decided to try the LRC-TriCEPS approach to identify cell-surface binding partners for the ligand after several earlier aborted attempts using different techniques. Using LRC-TriCEPS we have identified targets that we have now been able to verify functionally and biochemically using other methods. It was a pleasure to work with Dr Paul Helbling and his team who were extremely helpful guiding us through the experimental process and assisting with analysis of the data. We were impressed by the quality of the data and the ease with which we were able to run the study.

Dualsystems_testimonial_erasmus_MC

Dr Patric Delhanty
Laboratory of Metabolism and Reproduction
Department of Internal Medicine
Erasmus MC
Rotterdam, The Netherlands

2020-04-28T11:54:52+00:00

https://www.dualsystems.com/testimonials/department-of-internal-medicine-erasmus-mc/

Seoul National University

"I have used many binding assays and was in the verge of giving up. Then I have contacted Dr. Paul Helbling and his group. The LRC-TriCEPS experiment was effective and let us go over the obstacle we had during the project. We look forward to using TriCEPS in the future".

Dualsystems_Biotech_Testimonials_Seoul_National_University

Chung Hwan Cho, Ph. D. candidate
Environmental Health Microbiology Laboratory
Department of Environmental Public Health
Seoul National University

2020-01-29T14:05:52+00:00

"I have used many binding assays and was in the verge of giving up. Then I have contacted Dr. Paul Helbling and his group. The LRC-TriCEPS experiment was effective and let us go over the obstacle we had during the project. We look forward to using TriCEPS in the future". Chung Hwan Cho, Ph. D. candidate Environmental Health Microbiology Laboratory Department of Environmental Public Health Seoul National University

https://www.dualsystems.com/testimonials/seoul-national-university/

Immuno-Oncology Discovery from Bristol-Myers Squibb published in Nature

„Vista is an acidic pH selective ligand for PSGL-1“

Identification of a new immune-oncology drug target using the LRC-TriCEPS platform on primary human T-cells.

2019-10-30T06:05:00+00:00

„Vista is an acidic pH selective ligand for PSGL-1“ Identification of a new immune-oncology drug target using the LRC-TriCEPS platform on primary human T-cells.

https://www.dualsystems.com/testimonials/immuno-oncology-discovery-from-bristol-myers-squibb-published-in-nature/

The University of Oklahoma – Health Sciences Center

I was very pleased with my collaboration with the team at Dualsystems. We had to work with difficult cells and the team helped us develop modifications to the original protocol to be able to use the TriCEPS approach with our cells. The whole team was very responsive, involved, and knowledgeable and this led to a successful identification of a receptor for our ligand of interest. We have since then confirmed the interaction and we are now getting ready to publish this study, which will have implications in the treatment of ocular injuries.

Anne Kasus-Jacobi, PhD
Associate Professor of Research
University of Oklahoma Health Sciences Center
Department of Pharmaceutical Sciences
Oklahoma City, Oklahoma, USA

2019-07-02T04:38:05+00:00

https://www.dualsystems.com/testimonials/the-university-of-oklahoma-health-sciences-center/

CuroNZ Ltd

The team from DualSystems Biotech AG has been extremely helpful in delivering scientific advice for CuroNZ’s target identification journey. The quick turnaround time and the precision of NRP2945’s target identification in regard to the utilization of their TRICEPS technology impressed us very much. Meanwhile we could identify another NRP2945 receptor target that was identified by DualSystems as being recruited to the NRP2945-activated membrane receptor complex. An absolute pleasure to work with Paul Helbling’s team.

Frank Sieg, PhD
CSO
CuroNZ Ltd
Mangawhai in New Zealand

2019-02-20T12:18:04+00:00

https://www.dualsystems.com/testimonials/curonz-ltd/

University of Pittsburgh

It was a pleasure working with Paul Helbling and his team. I was impressed by their attention to detail, and optimization of all cell conditions to produce the most reliable possible results. They kept me informed at every stage of the process and shared data as soon as they were able to. Using their LRC-TriCEPS platform, we were able to follow leading candidates as binding partners for our cardiac targeting peptide and identified the most likely binding partner.

Maliha Zahid, M.D., Ph.D.
Assistant Professor
Departement of Developmental Biology
University of Pittsburgh

2018-11-15T19:35:14+00:00

https://www.dualsystems.com/testimonials/university-of-pittsburgh/

University of Oklahoma Health Sciences Center

I was very pleased with my collaboration with the team at Dualsystems. We had to work with difficult cells and the team helped our lab develop modifications to the original protocol to be able to use the TriCEPS approach with our cells. The whole team was very responsive, involved, and knowledgeable and this led to a successful identification of a receptor for our ligand of interest. We have since then confirmed this interaction and we are now getting ready to publish this study, which will have implications in the treatment of ocular injuries.

Anne Kasus-Jacobi, PhD
Assistant Professor of Research
University of Oklahoma Health Sciences Center
Department of Pharmaceutical Sciences
Oklahoma City, Oklahoma, USA

2018-04-23T11:45:16+00:00

https://www.dualsystems.com/testimonials/lrc-triceps/

Biomedical Research Institute

PUBLICATION: Li Z, Zeppa JJ, Hancock MA, McCormick JK, Doherty TM, Hendy GN, and Madrenas J. Staphylococcal Superantigens Use LAMA2 as a Coreceptor To Activate T Cells. J Immunol. 2018; 200: 1471-1479.

The identification of a T cell co-receptor for staphylococcal superantigens had been challenging due to the structural features of the interaction and its kinetics. However, working with Dualstystems Biotech AG, and with Dr. Paul Helbling in particular, and using the LRC-TriCEPS technology, we were able to identify a candidate that was subsequently corroborated by biochemical and functional assays. We are very happy with this collaboration , and sincerely recommend it for the identification of novel receptor or co-receptor candidates.(Quim) Madrenas, MD, PhD, FCAHS
Chief Scientific Officer
Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center
Torrance, USA

2018-04-19T11:18:18+00:00

PUBLICATION: Li Z, Zeppa JJ, Hancock MA, McCormick JK, Doherty TM, Hendy GN, and Madrenas J. Staphylococcal Superantigens Use LAMA2 as a Coreceptor To Activate T Cells. J Immunol. 2018; 200: 1471-1479. The identification of a T cell co-receptor for staphylococcal superantigens had been challenging due to the structural features of the interaction and its kinetics. However, working with Dualstystems Biotech AG, and with Dr. Paul Helbling in particular, and using the LRC-TriCEPS technology, we were able to identify a candidate that was subsequently corroborated by biochemical and functional assays. We are very happy with this collaboration , and sincerely recommend it for the identification of novel receptor or co-receptor candidates.(Quim) Madrenas, MD, PhD, FCAHS Chief Scientific Officer Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center Torrance, USA

https://www.dualsystems.com/testimonials/lrc-triceps-service-8/

QIMR Berghofer Medical Research Institute

“With the help of the team at Dualsystems we confirmed a potential receptor which has lead to a Nature paper submission and successful funding of a research grant. The LRC-TriCEPS experiment was straightforward and the process was cost effective. We look forward to using TriCEPS in the future.”

Anita Burgess | PhD
Hepatic Fibrosis Group
QIMR Berghofer Medical Research Institute, Australia

2017-12-12T13:21:33+00:00

https://www.dualsystems.com/testimonials/lrc-triceps-service-7/

University of Miami, Miller School of Medicine

We are very pleased with the experience and interaction on very high professional level with Dualsystems Biotech. As a result of such collaboration the new receptor MUC5B was identified in human chondrosarcoma cells for the first time for antiproliferative neuropeptide PRP-1. Read more
I would like to thank once again the company and, particularly, Dr Helbling for his attention and collaboration.

Dr Karina Galoian
Research associate professor
University of Miami, Miller School of Medicine
Department of Orthopedic surgery
Miami, Florida, USA

2017-11-16T08:07:04+00:00

We are very pleased with the experience and interaction on very high professional level with Dualsystems Biotech. As a result of such collaboration the new receptor MUC5B was identified in human chondrosarcoma cells for the first time for antiproliferative neuropeptide PRP-1. Read more I would like to thank once again the company and, particularly, Dr Helbling for his attention and collaboration. Dr Karina Galoian Research associate professor University of Miami, Miller School of Medicine Department of Orthopedic surgery Miami, Florida, USA

https://www.dualsystems.com/testimonials/lrc-triceps-service-6/

Münster University Hospital (UKM)

Dr. rer. nat. Martin Herold
Working group from Prof. Dr. med. Luisa Klotz
Münster University Hospital (UKM), Germany

2017-08-24T14:48:20+00:00

"Dualsystems Biotech’s approach to receptor identification with the TriCEPS reagent gave us a powerful platform with great support for a successful and fast data generation, when conventional approaches had previously failed."Dr. rer. nat. Martin Herold Working group from Prof. Dr. med. Luisa Klotz Münster University Hospital (UKM), Germany

https://www.dualsystems.com/testimonials/lrc-triceps-service-5/

University of Manitoba

Sari S. Hannila, PhD
Associate Professor, Department of Human Anatomy and Cell Science
Associate Member, Spinal Cord Research Centre
Max Rady College of Medicine, Rady Faculty of Health Sciences
University of Manitoba

2017-06-12T10:05:43+00:00

"Every aspect of our experience with Dualsystems Biotech was outstanding. They provided excellent customer service and technical support throughout the entire process. Their LRC-TriCEPS technology allowed us to identify several new candidate receptors for our protein of interest in rat primary neurons, and this has created new and exciting avenues for our research." Sari S. Hannila, PhD Associate Professor, Department of Human Anatomy and Cell Science Associate Member, Spinal Cord Research Centre Max Rady College of Medicine, Rady Faculty of Health Sciences University of Manitoba

https://www.dualsystems.com/testimonials/lrc-service/

The Rockefeller University

"We are very pleased with the work product of Dualsystems Biotech. The TriCEPS reagent allowed us to identify a novel ligand-extracellular matrix protein receptor interaction, which was not possible using traditional techniques. The Dualsystems team were very helpful in tailoring the experimental conditions to fit our biological question."

Manish Ponda, M.D., M.S.
Assistant Professor of Clinical Investigation
The Rockefeller University

2016-10-10T14:21:51+00:00

https://www.dualsystems.com/testimonials/lrc-triceps-service-3/

Medizinische Hochschule Hannover

“With the support of Dualsystems Biotech and their LRC-TriCEPS technology we were able to identify receptor candidates for our peptide with renoprotective properties in kidney injury.”

Dr. rer. nat. Inga Sörensen-Zender
Postdoc
Medizinische Hochschule Hannover

2016-09-26T10:26:51+00:00

“With the support of Dualsystems Biotech and their LRC-TriCEPS technology we were able to identify receptor candidates for our peptide with renoprotective properties in kidney injury.” Dr. rer. nat. Inga Sörensen-Zender Postdoc Medizinische Hochschule Hannover

https://www.dualsystems.com/testimonials/lrc-triceps-service-2/

East Tennessee State University

“For the ligand sample two unique receptors were identified. Flow cytometry analysis with siRNA induced knockdown of these proteins confirmed that the presence of the protein is needed for CTRP3 binding to occur. CONCLUSION The LRC-TriCEPS methodology was successful in identifying the receptor for CTRP3.”

Jonathan M Peterson
Assistant Professor
East Tennessee State University

2016-05-30T15:20:03+00:00

“For the ligand sample two unique receptors were identified. Flow cytometry analysis with siRNA induced knockdown of these proteins confirmed that the presence of the protein is needed for CTRP3 binding to occur. CONCLUSION The LRC-TriCEPS methodology was successful in identifying the receptor for CTRP3.”Jonathan M Peterson Assistant Professor East Tennessee State University

https://www.dualsystems.com/testimonials/lrc-triceps-service/

Igenica Biotherapeutics

«Leveraging Dualsystems Biotech novel linker technology (LRC-TriCEPS) and its analytical data processing capabilities we were able to identify the heterophilic receptor for a highly-pursued immuno-oncology target.»Dr. Edward van der Horst,
Senior Director, Preclinical Development
Igenica Biotherapeutics

2016-05-09T11:13:08+00:00

«Leveraging Dualsystems Biotech novel linker technology (LRC-TriCEPS) and its analytical data processing capabilities we were able to identify the heterophilic receptor for a highly-pursued immuno-oncology target.»Dr. Edward van der Horst, Senior Director, Preclinical Development Igenica Biotherapeutics

https://www.dualsystems.com/testimonials/lrc-triceps-service-4/

Centro de Estudos de Doenças Crónicas

New publication in Nature Communications using the LRC-TriCEPS technology in collaboration with Alisson Gontijo
« The fruitful collaboration with Dualsystems Biotech using the LRC-TriCEPS (CaptiRec) technology showed that even on insect cells receptors could be identified »

Alisson M. Gontijo,
Principal Investigator at CEDOC
Centro de Estudos de Doenças Crónicas

2015-02-24T07:32:40+00:00

New publication in Nature Communications using the LRC-TriCEPS technology in collaboration with Alisson Gontijo « The fruitful collaboration with Dualsystems Biotech using the LRC-TriCEPS (CaptiRec) technology showed that even on insect cells receptors could be identified » Alisson M. Gontijo, Principal Investigator at CEDOC Centro de Estudos de Doenças Crónicas

https://www.dualsystems.com/testimonials/captirec-service-3/

Washington University School of Medicine

"Thanks to LRC-TriCEPS (CaptiRec) technology we were able to identify a long sought receptor of our ligand using genetically-engineered cell lines with the support of Dualsystems".Fumihiko Urano, MD, PhD
Samuel E. Schechter Professor of Medicine
Washington University School of Medicine

2015-02-17T14:30:12+00:00

"Thanks to LRC-TriCEPS (CaptiRec) technology we were able to identify a long sought receptor of our ligand using genetically-engineered cell lines with the support of Dualsystems".Fumihiko Urano, MD, PhD Samuel E. Schechter Professor of Medicine Washington University School of Medicine

https://www.dualsystems.com/testimonials/captirec-service-2/

University of California San Francisco

De'Broski R. Herbert Ph.D.
Assistant Professor in Residence
University of California San Francisco (UCSF)

2015-02-17T14:27:53+00:00

"We have been trying to identify a receptor that has been sought after for nearly 30 years by laboratories across the globe. Thanks to Dualsystems service CaptiRec (LRC-TriCEPS), we now have a strong candidate receptor." De'Broski R. Herbert Ph.D. Assistant Professor in Residence University of California San Francisco (UCSF)

https://www.dualsystems.com/testimonials/captirec-service/

LRC-TriCEPS customers worldwide

Over 200 satisfied customers from 28 countries.

Customers worldwide

10+

Years working with LRC-TriCEPS

200+

LRC-TriCEPS clients served

50+

Cell types used for LRC-TriCEPS

23+

Years of experience

Areas of expertise

Specialized in identifying targets and off targets on living cells to elucidate the mode of action.
Experts in proteomics, LC-MS/MS analyses, and cell biology.

Affinity & receptor expression

Using antibodies with different affinities against the same targets on cells expressing the targets on different levels.

More about

Example of LRC-TriCEPS

Example of the results of an LRC-TriCEPS experiment with the deliverables.

More about

LRC-TriCEPS on human primary T-cells

Primary T-cells are used for target identification and to elucidate cell-cell interactions.

More about

Company

Dualsystems Biotech is a provider of proteomics services for industry and academia.

More about

FAQs

Find answers to your questions or just give us a call.

More about

Publication

Find publications using LRC-TriCEPS or HATRIC-LRC platforms for target identification.

More about

LRC-TriCEPS publications

Publications

LRC-TriCEPS / HATRIC-LRC Publications

Concerning the LRC-TriCEPS or HATRIC-LRC platforms.

Use of LRC-TriCEPS to characterize the surfaceome of extracellular vesicles (EV)

Intro

Presented at the annual meeting of the International Society for Extracellular Vesicles (ISEV) 2025 Annual Meeting in April

PDF for download

Abstract

Advancing EV Research: Novel Technique for EV’s Surfaceome Profiling.

The extracellular vesicle (EV) surfaceome plays a crucial role in vesicle targeting, uptake, and functional interactions. However, its
characterization remains challenging due to EV heterogeneity and small size, limiting conventional proteomics approaches.
In this study, we employed a chemoproteomic approach originally designed for the identification of cell surface proteins in living cells,
and adapted it for the untargeted profiling of EV surfaceome. This methodology uses selective enrichment of N-, C-, and Oglycosylated
proteins, which are ubiquitously present on the plasma membrane of living cells and, by extension, on the EV surface.

Author

The LRC-TriCEPS platform identified 2 new receptors for ApoA-1, potentially new drug targets for Diabetes Type 2

Intro

Apolipoprotein A-I priming via SR-BI and ABCA1 receptor binding upregulates mitochondrial metabolism to promote insulin secretion in INS-1E cells

Abstract

Abstract :

Apolipoprotein A-I (ApoA-I), the primary component of high-density lipoprotein (HDL) cholesterol primes β-cells to increase>INS secretion, however, the mechanisms involved are not fully defined. Here, we aimed to confirm ApoA-I receptors in β-cells and delineate ApoA-I-receptor pathways in β-cell>INS output. An LRC-TriCEPS experiment was performed using the INS-1E rat β-cell model and ApoA-I for unbiased identification of ApoA-I receptors. We confirm that SR-BI and ABCA1 are the primary β-cell ApoA-I receptors and demonstrate that ApoA-I priming enhances β-cell>INS secretion via the upregulation of mitochondrial metabolism through ApoA-I-SR-BI and ApoA-I-ABCA1 pathways. We propose that SR-BI relies on mitochondrial and exocytotic pathways, while ABCA1 depends solely on mitochondrial pathways. Our findings uncover new targets in ApoA-I β-cell mechanism for type 2 diabetes therapies.

https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0311039

Author

Identification of a receptor for house dust mite allergens

Intro

Link PDF

Link to the News Release Details

Abstract

Development of therapies with the potential to change the allergic asthmatic disease course will require the discovery of targets that play a central role during the initiation of an allergic response, such as those involved in the process of allergen recognition. We use a receptor glycocapture technique to screen for house dust mite (HDM) receptors and identify LMAN1 as a candidate. We verify the ability of LMAN1 to directly bind HDM allergens and demonstrate that LMAN1 is expressed on the surface of dendritic cells (DCs) and airway epithelial cells (AECs) in vivo. Overexpression of LMAN1 downregulates NF-κB signaling in response to inflammatory cytokines or HDM. HDM promotes binding of LMAN1 to the FcRγ and recruitment of SHP1. Last, peripheral DCs of asthmatic individuals show a significant reduction in the expression of LMAN1 compared with healthy controls. These findings have potential implications for the development of therapeutic interventions for atopic disease.

Author

LRC-TriCEPS identified a completely new mechanism of monocyte activation that might be clinically relevant in Alzheimers’ and inflammation diseases. Feb 2023

Intro

PDF

Abstract

The emerging cytokine tissue inhibitor of metalloproteinases-1 (TIMP-1) correlates with the progression of inflammatory diseases, including cancer. However, the effects of TIMP-1 on immune cell activation and underlying molecular mechanisms are largely unknown. The LRC-TriCEPS platform revealed TIMP-1-interaction with Amyloid Precursor Protein (APP) family members. We found that TIMP-1 triggered glucose uptake and flammatory cytokine expression in human monocytes. In cancer patients, TIMP-1 expression positively correlated with flammatory cytokine expression and processes associated with monocyte activation. This novel monocyte activation pathway might be clinically relevant for inflammation diseases such as pancreatic cancer but might also be involved in Alzheimers’.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9837626/

Author

Sensei Biotherapeutics Presents Preclinical Data at the 37th Society for Immunotherapy of Cancer (SITC) Annual Meeting

Abstract

Author

Identification of key extracellular binding proteins

Intro

Identification of key extracellular binding proteins implicate role in inflammation and fibrosis for alanyl- and aspartyl-tRNA synthetases

Abstract

Author

Latrophilin-2 is a novel receptor of LRG1

Intro

Latrophilin-2 is a novel receptor of LRG1 that rescues vascular and neurological abnormalities and restores diabetic erectile function – Diabetes mellitus (DM) is a chronic metabolic disorder that involves endothelial dysfunction and neuropathy and can lead to multiple complications, including cardiovascular disease, stroke, chronic kidney disease, foot ulcers, and retinopathy¹. DM is also a major cause of erectile dysfunction (ED), which is a manifestation of microangiopathy and neuropathy¹. Approximately 50–75% of male diabetic patients have ED². Phosphodiesterase type 5 (PDE5) inhibitors are the most commonly used first-line treatment options for ED; however, these agents are ineffective in ~30% of patients and ultimately cannot rescue angiopathy and neuropathy in diabetic ED patients³. Tested alternative therapeutic options for ED include various angiogenic or neurotrophic factors, such as COMP-Ang1, vascular endothelial growth factor (VEGF), dickkopf2, neurotrophin-3 (NT3), and brain-derived neurotrophic factor (BDNF)^4,5,6,7,8; however, these treatments have shown limited success in clinical trials.

Experimental & Molecular Medicine volume 54, pages626–638 (2022) Cite this article

PDF and Link to the nature.com

Abstract

Diabetes mellitus (DM) is a chronic metabolic disorder characterized by inappropriate hyperglycemia, which causes endothelial dysfunction and peripheral neuropathy, ultimately leading to multiple complications. One prevalent complication is diabetic erectile dysfunction (ED), which is more severe and more resistant to treatment than nondiabetic ED. The serum glycoprotein leucine-rich ɑ-2-glycoprotein 1 (LRG1) is a modulator of TGF-β-mediated angiogenesis and has been proposed as a biomarker for a variety of diseases, including DM. Here, we found that the adhesion GPCR latrophilin-2 (LPHN2) is a TGF-β-independent receptor of LRG1. By interacting with LPHN2, LRG1 promotes both angiogenic and neurotrophic processes in mouse tissue explants under hyperglycemic conditions. Preclinical studies in a diabetic ED mouse model showed that LRG1 administration into the penile tissue, which exhibits significantly increased LPHN2 expression, fully restores erectile function by rescuing vascular and neurological abnormalities. Further investigations revealed that PI3K, AKT, and NF-κB p65 constitute the key intracellular signaling pathway of the LRG1/LPHN2 axis, providing important mechanistic insights into LRG1-mediated angiogenesis and nerve regeneration in DM. Our findings suggest that LRG1 can be a potential new therapeutic option for treating aberrant peripheral blood vessels and neuropathy associated with diabetic complications, such as diabetic ED

Author

Akkermansia muciniphila secretes a gluc.-like peptide-1-inducing protein that improves glucose homeostasis and ameliorates metabolic disease in mice

Intro

Nature Microbiol (2021) https://doi.org/10.1038/s41564-021-00880-5

Abstract

Here, we report that A. muciniphila increases thermogenesis and gluc.-like peptide-1 (GLP-1) secretion in high-fat-diet (HFD)-induced C57BL/6J mice by induction of uncoupling protein 1 in brown adipose tissue and systemic GLP-1 secretion. We apply fast protein liquid chromatography and liquid chromatography coupled to mass spectrophotometry analysis to identify an 84 kDa protein, named P9, that is secreted by A. muciniphila. Using L cells and mice fed on an HFD, we show that purified P9 alone is sufficient to induce GLP-1 secretion and brown adipose tissue thermogenesis. Using ligand–receptor capture analysis, we find that P9 interacts with intercellular adhesion molecule 2 (ICAM-2). Interleukin-6 deficiency abrogates the effects of P9 in glucose homeostasis and downregulates ICAM-2 expression. Our results show that the interactions between P9 and ICAM-2 could be targeted by therapeutics for metabolic diseases.

Author

Neuroplastin Modulates Anti-inflammatory Effects of MANF

Intro

iScience Volume 23, ISSUE 12, 101810, December 18, 2020, DOI:https://doi.org/10.1016/j.isci.2020.101810

Abstract

Identification of Neuroplastin (NPTN) as receptor of MANF polypeptide by LRC-TriCEPS. Endoplasmic reticulum (ER) stress is known to induce pro-inflammatory response and ultimately leads to cell death. Mesencephalic astrocyte-derived neurotrophic factor (MANF) is an ER-localized protein whose expression and secretion is induced by ER stress and a crucial survival factor. However, the underlying mechanism of how MANF exerts its cytoprotective activity remains unclear due to the lack of knowledge of its receptor. Here we show that Neuroplastin (NPTN) is such a receptor for MANF. Biochemical analysis shows the physiological interaction between MANF and NPTN on the cell surface. Binding of MANF to NPTN mitigates the inflammatory response and apoptosis via suppression of NF-kβ signaling. Our results demonstrate that NPTN is a cell surface receptor for MANF, which modulates inflammatory responses and cell death, and that the MANF-NPTN survival signaling described here provides potential therapeutic targets for the treatment of ER stress-related disorders, including diabetes mellitus, neurodegeneration, retinal degeneration, and Wolfram syndrome.

Author

NKG2A/CD94 Is a New Immune Receptor for HLA-G and Distinguishes Amino Acid Differences in the HLA-G Heavy Chain

Intro

International Journal of Molecular Sciences. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7352787/

Abstract

The immune checkpoint molecule human leukocyte antigen (HLA)-G is upregulated on malignant cells but not on healthy surrounding cells, the requirement of understanding the basis of receptor mediated events at the HLA-G/NK cell interface becomes obvious. The NK cell receptors ILT2 and KIR2DL4 have been described to bind to HLA-G; however, their differential function and expression levels on NK cell subsets suggest the existence of an unreported receptor. Here, we performed a ligand-based receptor capture on living cells utilizing sHLA-G*01:01 molecules coupled to TriCEPS and bound to NK cells followed by mass spectrometric analyses. We could define NKG2A/CD94 as a cognate receptor of HLA-G.

Author

Antimicrobial Peptides Derived from the Immune, Defense Protein CAP37 Inhibit TLR4 Activation by S100A9

Intro

METHODS. We used a TriCEPS-based, ligand-receptor glycocapture method to identify the
binding partners of CAP37 on live human corneal epithelial cells using the hTCEpi cell
line. We used an ELISA method to confirm binding with identified partners and test the
binding with CAP37-derived peptides. We used a reporter cell line to measure activation
of the identified membrane receptor by CAP37 and derived peptides.

Abstract

RESULTS. We pulled down S100 calcium-binding protein A9 (S100A9) as a binding partner
of CAP37 and found that CAP37 and four derived peptides encompassing two regions of
CAP37 bind S100A9 with high affinities. We found that CAP37 and the S100A9-binding
peptides could also directly interact with the Toll-like receptor 4 (TLR4), a known receptor
for S100A9. CAP37 and one peptide partially activated TLR4. The other three peptides
did not activate TLR4. Finally, we found that CAP37 and all four peptides could inhibit
the activation of TLR4 by S100A9.

CONCLUSIONS. This study identifies a mechanism of action for CAP37 and derived antimicrobial
peptides that may restrain inflammatory responses to corneal injury and favor
corneal re-epithelialization.
PDF

Link

Author

Acidity changes immunology: a new VISTA pathway

Intro

Nature Immunology volume 21, pages13–16 (2020)

Abstract

Using the LRC-TriCEPS platform PSGL-1 was identified as the interaction partner of the co-inhibitor Vista on activated primary T-cells as at acidic pH mimicking the acidic tumour environment
Now, Vista tumour immunotherapy can rationally move forward
The results also suggest to use also acidity as therapeutic target for tumour therapy
Now also other interactions at acidic pH for drug candidates or co-inhibitor interactions should be tested on primary T-cells. It could explain why some drug candidates are not successful in later development.

Author

Binding to carboxypeptidase M mediates protective effects of fibrinopeptide Bβ

Intro

https://doi.org/10.1016/j.trsl.2019.07.008, Translational Research Volume 213, Sörensen-Zender et al.

Abstract

A 28-amino-acid fibrinopeptide (Bb15-42) was studied for kidney protection using human HK-2 tubular cells. The LRC-TriCEPS platform enabled the discovery of carboxypeptidase M (CBPM) as a novel cell surface receptor for Bb15-42, revealing a new protective mechanism independent of endothelial VE-cadherin. This work is important as it identifies CBPM as a therapeutic target for renal injury, illustrating the unique power of LRC-TriCEPS to uncover receptor-ligand interactions directly on living cells.

Author

Nature Article VISTA interaction with PSGL-1 identified by LRC-TriCEPS

Intro

https://www.nature.com/articles/s41586-019-1674-5 Nature volume 574, pages565–570 (2019)

Abstract

Summary We then performed ligand-based receptor capture with VISTA–Fc chimeric protein and human CD4 + Tcells at acidic pH 19 . PSGL-1 was one of few proteins that were enriched relative to controls (Fig.3a). In addition to its well-characterized role facilitating adhesion interactions between leukocytes, platelets and endothelial cells 20,21 , PSGL-1 has been identified as a negative regulator of T cell responses in contexts of chronic viral infection, cancer, and some autoimmune diseases 22–28 .

Author

Robert J. Johnston, Linhui Julie Su, Jason Pinckney, David Critton, Eric Boyer, Arathi Krishnakumar, Martin Corbett, Andrew L. Rankin, Rose Dibella, Lynne Campbell, Gaelle H. Martin, Hadia Lemar, Thomas Cayton, Richard Y.-C. Huang, Xiaodi Deng, Akbar Nayeem, Haibin Chen, Burce Ergel, Joseph M. Rizzo, Aaron P. Yamniuk, Sanjib Dutta, Justine Ngo, Andrea Olga Shorts, Radha Ramakrishnan, Alexander Kozhich, Jim Holloway, Hua Fang, Ying-Kai Wang, Zheng Yang, Kader Thiam, Ginger Rakestraw, Arvind Rajpal, Paul Sheppard, Michael Quigley, Keith S. Bahjat & Alan J. Korman

Anti-VISTA antibody that inhibits Vista function and blocks interaction with PSGL-1 and VSIG3 proteins slows tumor growth

Intro

https://www.nature.com/articles/s41598-020-71519-4 Mehta, N., Maddineni, S., Kelly, R.L. et al. An engineered antibody binds a distinct epitope and is a potent inhibitor of murine and human VISTA. Sci Rep 10, 15171 (2020). https://doi.org/10.1038/s41598-020-71519-4 PDF

Abstract

Author

Phage resistance at the cost of virulence

Intro

Phage resistance at the cost of virulence: Listeria monocytogenes serovar 4b requires galactosylated teichoic acids for InlBmediated invasion
PLOS Pathogens | https://doi.org/10.1371/journal.ppat.1008032 October 7, 2019
PDF

Abstract

L. monocytogenes is a Gram-positive, food-borne, intracellular pathogen that causes severe infection in susceptible individuals. Interestingly, almost all infections are caused by a subset of strains belonging to certain serovars featuring a complex glycosylation pattern on their cell surface. Using an engineered bacteriophage that specifically recognizes these modifications we selected for mutants that lost these sugars. We found that the resulting strains are severely deficient in invading host cells as we observed that a major virulence factor mediating host cell entry requires galactose decoration of the cell surface for its function. Without this galactose decoration, the strain represents a serovar not associated with disease. Altogether, we show a complex interplay between bacteriophages, bacteria, and the host, demonstrating that cellular invasiveness is dependent upon a serovar-defining structure, which also serves as a phage receptor.

Author

TFF3 interacts with LINGO2 to regulate EGFR activation for protection against colitis and gastrointestinal helminths

Intro

Nature Communications volume 10, Article number: 4408 (2019) https://doi.org/10.1038/s41467-019-12315-1

Abstract

Intestinal epithelial cells (IEC) have important functions in nutrient absorption, barrier integrity, regeneration, pathogen-sensing, and mucus secretion. Goblet cells are a specialized cell type of IEC that secrete Trefoil factor 3 (TFF3) to regulate mucus viscosity and wound healing, but whether TFF3-responsiveness requires a receptor is unclear. We postulated that TFF3 interacted with its receptor through low-affinity interactions reliant upon carbohydrates because TFF3 glycosylation has been shown critical for biological activity34,35, therefore U937 cells were subjected to the TRICEPSTM protocol as a biochemical screening strategy to identify glycosylated transmembrane protein(s) on the cell surface32,36. As bait, rhTFF3 was covalently linked to the TRICEPS probe and incubated with PMA-treated U937 that had been treated with sodium periodate. Cell pellets were subjected to glycosidase digestion and peptides generated using mass spectrometry. As a positive control to account for enrichment efficiency, recombinant human>INS was used as bait for the>INS receptor. Whereas the TFF3-probe induced an 8-fold enrichment of LINGO2 (LIGO2) peptide, the>INS-probe induced a 7.76-fold-enrichment in INSR peptide (Fig. 1b). No other enriched peptides in this screen met this level of enrichment or were derived from proteins that satisfied our selection criterion (e.g., extracellular domain, transmembrane region, cytoplasmic tail).Here, we show that leucine rich repeat receptor and nogo-interacting protein 2 (LINGO2) is essential for TFF3-mediated functions. LINGO2 immunoprecipitates with TFF3, co-localizes with TFF3 on the cell membrane of IEC, and allows TFF3 to block apoptosis. We further show that TFF3-LINGO2 interactions disrupt EGFR-LINGO2 complexes resulting in enhanced EGFR signaling. Excessive basal EGFR activation in Lingo2 deficient mice increases disease severity during colitis and augments immunity against helminth infection. Conversely, TFF3 deficiency reduces helminth immunity. Thus, TFF3-LINGO2 interactions de-repress inhibitory LINGO2-EGFR complexes, allowing TFF3 to drive wound healing and immunity.

Author

Nicole Maloney Belle 1, Yingbiao Ji 1,5, Karl Herbine 1,5, Yun Wei 2, 3,5, JoonHyung Park 1,5, Kelly Zullo1, Li-Yin Hung 1,2, Sriram Srivatsa 1, Tanner Young 1, Taylor Oniskey 2, Christopher Pastore 1, Wildaliz Nieves 4, Ma Somsouk 4 & De’Broski R. Herbert 1,2 1 Department of Pathobiology, University of Pennsylvania School of Veterinary Medicine, Philadelphia, PA 19140, USA. 2 Division of Experimental Medicine, University of California, San Francisco, San Francisco, CA 94110, USA. 3 Department of Inflammation and Oncology, Amgen Inc., 1120 Veterans Boulevard, South San Francisco, CA 94080, USA. 4 Division of Gastroenterology at ZSFG, University of California, San Francisco, San Francisco, CA 94110, USA. 5These authors contributed equally: Yingbiao Ji, Karl Herbine, Yun Wei, JoonHyung Park. Email: debroski@vet.upenn.edu

White Paper Ligand-Receptor Identification Methodologies Details Matter

Reference

European Biopharmaceutical Review April 2019, pages 16-20 / Maria P. Pavlou and Paul Helbling / White -Paper PDF

Abstract

Author

Validation of extracellular ligand–receptor interactions by Flow‑TriCEPS

Reference

BMC Research Notes 2018 11:863 https://doi.org/10.1186/s13104-018-3974-5 Laura A. Lopez‑Garcia, Levent Demiray, Sandra Ruch‑Marder, Ann‑Katrin Hopp, Michael O. Hottiger, Paul M. Helbling and Maria P. Pavlou Received: 28 October 2018 – Accepted: 30 November 2018- Published: 5 December 2018 PDF

Abstract

The advent of ligand based receptor capture methodologies, allows the identification of unknown receptor candidates for orphan extracellular ligands. However, further target validation can be tedious, laborious and time consuming. Here, we present a methodology that provides a fast and costefficient alternative for candidate target verification on living cells for a peptide, a protein and an antibody.

Author

Cardiac Targeting Peptide, a Novel Cardiac Vector: Studies in Bio-Distribution, Imaging Application, and Mechanism of Transduction

Refernce

Maliha Zahid, Kyle S. Feldman, Gabriel Garcia-Borrero, Timothy N. Feinstein, Nicholas Pogodzinski, Xinxiu Xu, Raymond Yurko, Michael Czachowski , Yijen L. Wu, Neale S. Mason and CeciliaW. Lo Biomolecules 2018, 8, 147; doi:10.3390/biom8040147 Received: 24 September 2018 / Accepted: 8 November 2018 / Published: 14 November 2018

Abstract

Our previous work identified a 12-amino acid peptide that targets the heart, termed cardiac targeting peptide (CTP).We now quantitatively assess the bio-distribution of CTP, show a clinical application with the imaging of the murine heart, and study its mechanisms of transduction. Bio-distribution studies of cyanine5.5-N-Hydroxysuccinimide (Cy5.5) labeled CTP were undertaken in wild-type mice. Cardiac targeting peptide was labeled with Tc. 99m (99mTc) using the chelator hydrazino-nicotinamide (HYNIC), and imaging performed using micro-single photon emission computerized tomography/computerized tomography (SPECT/CT). Human-induced pluripotent stem cell (iPSC)-derived cardiomyocytes (CMCs) were incubated with dual-labeled CTP, and imaged using confocal microscopy. TriCEPs technology was utilized to study the mechanism of transduction. Bio-distribution studies showed peak uptake of CTP at 15 min. 99mTc-HYNIC-CTP showed heart-specific uptake. Robust transduction of beating human iPSC-derived CMCs was seen. TriCEPs experiments revealed five candidate binding partners for CTP, with Kcnh5 being felt to be the most likely candidate as it showed a trend towards being competed out by siRNA knockdown. Transduction efficiency was enhanced by increasing extracellular potassium concentration, and with Quin., a Kcnh5 inhibitor, that blocks the channel in an open position. We demonstrate that CTP transduces the normal heart as early as 15 min. 99mTc-HYNIC-CTP targets the normal murine heart with substantially improved targeting compared with 99mTc Sestamibi. Cardiac targeting peptide’s transduction ability is not species limited and has human applicability. Cardiac targeting peptide appears to utilize Kcnh5 to gain cell entry, a phenomenon that is affected by pre-treatment with Quin. and changes in potassium levels.

Author

Maliha Zahid 1,*, Kyle S. Feldman 1, Gabriel Garcia-Borrero 1, Timothy N. Feinstein 1, Nicholas Pogodzinski 1, Xinxiu Xu 1, Raymond Yurko 2, Michael Czachowski 3, Yijen L. Wu 1, Neale S. Mason 3 and CeciliaW. Lo 1 1 Department of Developmental Biology, University of Pittsburgh, Pittsburgh, PA 15201, USA; ksf23@pitt.edu (K.S.F.); gag44@pitt.edu (G.G.-B.); tnf8@pitt.edu (T.N.F.); nrp30@pitt.edu (N.P.);xux@pitt.edu (X.X.); yijenwu@pitt.edu (Y.L.W.); cel36@pitt.edu (C.W.L.) 2 Peptide Synthesis Facility, University of Pittsburgh, Pittsburgh, PA 15201, USA; yurko@pitt.edu 3 Department of Radiology, University of Pittsburgh, Pittsburgh, PA 15201, USA; michael.czachowski@chp.edu (M.C.); masonns@upmc.edu (N.S.M.)

Leukocyte differentiation by histidine-rich glycoprotein/stanniocalcin-2 complex regulates murine glioma growth through modulation of anti-tumor immunity

Reference

Francis P Roche, Ilkka Pietilä, Hiroshi Kaito, Elisabet O Sjöström, Nadine Sobotzki, Oriol Noguer, Tor Persson Skare, Magnus Essand, Bernd Wollscheid, Michael Welsh and Lena Claesson-Welsh DOI: 10.1158/1535-7163.MCT-18-0097 Received January 27, 2018, Revision received April 21, 2018, Accepted June 19, 2018, Copyright ©2018, American Association for Cancer Research. PDF

Abstract

The plasma-protein histidine-rich glycoprotein (HRG) is implicated in phenotypic switching of tumor-associated macrophages, regulating cytokine production and phagocytotic activity, thereby promoting vessel normalization and anti-tumor immune responses. To assess the therapeutic effect of HRG gene delivery on CNS tumors, we used adenovirus-encoded HRG to treat mouse intracranial GL261 glioma. Delivery of Ad5-HRG to the tumor site resulted in a significant reduction in glioma growth, associated with increased vessel perfusion and increased CD45+ leukocyte and CD8+ T cell accumulation in the tumor. Antibody-mediated neutralization of colony-stimulating factor-1 suppressed the effects of HRG on CD45+ and CD8+ infiltration. Using a novel protein interaction-decoding technology, TRICEPS-based ligand receptor capture (LRC), we identified Stanniocalcin-2 (STC2) as an interacting partner of HRG on the surface of inflammatory cells in vitro and co-localization of HRG and STC2 in gliomas. HRG reduced the suppressive effects of STC2 on monocyte CD14+ differentiation and STC2-regulated immune response pathways. In consequence, Ad5-HRG treated gliomas displayed decreased numbers of Interleukin-35+ Treg cells, providing a mechanistic rationale for the reduction in GL261 growth in response to Ad5-HRG delivery. We conclude that HRG suppresses glioma growth by modulating tumor inflammation through monocyte infiltration and differentiation. Moreover, HRG acts to balance the regulatory effects of its partner, STC2, on inflammation and innate and/or acquired immunity. HRG gene delivery therefore offers a potential therapeutic strategy to control anti-tumor immunity.

Author

Francis P Roche1, Ilkka Pietilä2, Hiroshi Kaito3, Elisabet O Sjöström1, Nadine Sobotzki4, Oriol Noguer1, Tor Persson Skare1, Magnus Essand1, Bernd Wollscheid5, Michael Welsh2, and Lena Claesson-Welsh1,*

¹Department of Immunology, Uppsala University

²Department of Medical Cell Biology, Uppsala University

³Department of Immunology, Uppsala university

⁴Department of Health Sciences, ETH Zurich

⁵Department of Health Sciences, ETH Zürich

↵* Corresponding Author:

Glycomics and Proteomics Approaches to Investigate Early Adenovirus–Host Cell Interactions

Reference

Lisa Lasswitz, Naresh Chandra, Niklas Arnberg, Gisa Gerold jmb Journal of Molecular Biology, doi.org/10.1016/j.jmb.2018.04.039 Received 15 February 2018, Revised 24 April 2018, Accepted 30 April 2018, Available online 7 May 2018.

Abstract

Adenoviruses as most viruses rely on glycan and protein interactions to attach to and enter susceptible host cells. The Adenoviridae family comprises more than 80 human types and they differ in their attachment factor and receptor usage, which likely contributes to the diverse tropism of the different types. In the past years, methods to systematically identify glycan and protein interactions have advanced. In particular sensitivity, speed and coverage of mass spectrometric analyses allow for high-throughput identification of glycans and peptides separated by liquid chromatography. Also, developments in glycan microarray technologies have led to targeted, high-throughput screening and identification of glycan-based receptors. The mapping of cell surface interactions of the diverse adenovirus types has implications for cell, tissue, and species tropism as well as drug development. Here we review known adenovirus interactions with glycan- and protein-based receptors, as well as glycomics and proteomics strategies to identify yet elusive virus receptors and attachment factors. We finally discuss challenges, bottlenecks, and future research directions in the field of non-enveloped virus entry into host cells.

Author

Lisa Lasswitz¹Naresh Chandra^2,3Niklas Arnberg^2,3Gisa Gerold^1,2,4
¹Institute for Experimental Virology, TWINCORE, Centre for Experimental and Clinical Infection Research, a joint venture between the Medical School Hannover and the Helmholtz Centre for Infection Research, 30625 Hannover, Germany

²Department of Clinical Microbiology, Virology, Umeå University, SE-90185 Umeå, Sweden

³Molecular Infection Medicine Sweden (MIMS), Umeå University, SE-90185 Umea, Sweden

⁴Wallenberg Centre for Molecular Medicine (WCMM), Umeå University, SE-90185 Umea, Sweden

Contact

Please contact us for more information

*Mandatory fields – please complete

Dualsystems Biotech AG

Dualsystems Biotech AG
Dr. Paul Helbling
Grabenstrasse 11a
8952 Schlieren
Switzerland

phone +41 44 738 50 00
fax +41 44 738 50 05

Contact Dr. Paul Helbling to discuss how we can support your projects.

info@dualsystems.com

Dualsystems Biotech is located in Schlieren (Zurich), close to the railway station.

Home

Do you know the targets of your ligand?

Flow TriCEPS / TAMRA-TriCEPS / Services/Kit

LRC-TriCEPS / LRC-HATRIC Services

Flow TriCEPS combined with siRNA knock down

How we support you

News Dualsystems

Licensing Agreement with ETH Zurich on LRC technoloy

Identify the mode of action using the TriCEPS platforms

Flow TriCEPS / TAMRA-TriCEPS

LRC-TriCEPS / LRC-HATRIC

Flow TriCEPS combined with siRNA knock down

We identify targets / off-targets of your ligand

Customers Testimonials – LRC-TriCEPS Service

Helmholtz Munich

University Hospital of Lausanne (CHUV)

OncoLille Cancer Institute

AstraZeneca

UCF College of Medicine

Cohbar

Technical University of Munich

University of Miyazaki

Lund University Diabetes Centre

Australian National University

Harvard Medical School, Brigham and Women’s Hospital

Center for Biomolecular & Cellular Structure, Institute for Basic Science

Department of Internal Medicine Erasmus MC

Seoul National University

Immuno-Oncology Discovery from Bristol-Myers Squibb published in Nature

The University of Oklahoma – Health Sciences Center

CuroNZ Ltd

University of Pittsburgh

University of Oklahoma Health Sciences Center

Biomedical Research Institute

QIMR Berghofer Medical Research Institute

University of Miami, Miller School of Medicine

Münster University Hospital (UKM)

University of Manitoba

The Rockefeller University

Medizinische Hochschule Hannover

East Tennessee State University

Igenica Biotherapeutics

Centro de Estudos de Doenças Crónicas

Washington University School of Medicine

University of California San Francisco

LRC-TriCEPS customers worldwide

Areas of expertise

Affinity & receptor expression

Example of LRC-TriCEPS

LRC-TriCEPS on human primary T-cells

Company

FAQs

Publication

LRC-TriCEPS publications

LRC-TriCEPS / HATRIC-LRC Publications

Contact

Please contact us for more information

Dualsystems Biotech AG

Footer

Dualsystems Biotech AG

LRC-TriCEPS Video

Social Media